Two companies have started an exclusive multi-year partnership to develop technologies for the Zoll LifeVest wearable defibrillator, according to a report in Technical Textiles.
Zoll Medical Corp. is an Asahi Kasei Group company that manufactures medical devices and related software solutions. Myant is a manufacturer melding technology and soft electronics with textiles and advancing human connectedness to the Internet of Things.
“We are excited to combine efforts with Myant and leverage their strong research and development capabilities, and broad research capabilities from its Centres for Excellence in Canada and the U.S.,” said Jason T. Whiting, president of Zoll LifeVest.
“We are blending the benefits of advancements in materials science, state-of-the art machines, yarn with nanotechnology, and advanced manufacturing,” said Tony Chahine, CEO and founder of Myant.
The LifeVest is used for a range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.